26 results on '"Chalfein, Ferryanto"'
Search Results
2. Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms
- Author
-
Wirjanata, Grennady, primary, Handayuni, Irene, additional, Zaloumis, Sophie G., additional, Chalfein, Ferryanto, additional, Prayoga, Pak, additional, Kenangalem, Enny, additional, Poespoprodjo, Jeanne Rini, additional, Noviyanti, Rintis, additional, Simpson, Julie A., additional, Price, Ric N., additional, and Marfurt, Jutta, additional
- Published
- 2016
- Full Text
- View/download PDF
3. Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry
- Author
-
Wirjanata, Grennady, Handayuni, Irene, Prayoga, Pak, Apriyanti, Dwi, Chalfein, Ferryanto, Sebayang, Boni F., Kho, Steven, Noviyanti, Rintis, Kenangalem, Enny, Campo, Brice, Poespoprodjo, Jeanne R., Price, Ric N., Marfurt, Jutta, Wirjanata, Grennady, Handayuni, Irene, Prayoga, Pak, Apriyanti, Dwi, Chalfein, Ferryanto, Sebayang, Boni F., Kho, Steven, Noviyanti, Rintis, Kenangalem, Enny, Campo, Brice, Poespoprodjo, Jeanne R., Price, Ric N., and Marfurt, Jutta
- Abstract
BackgroundThe emergence and spread of multidrug-resistant Plasmodium falciparum and Plasmodium vivax highlights the need for objective measures of ex vivo drug susceptibility. Flow cytometry (FC) has potential to provide a robust and rapid quantification of ex vivo parasite growth.MethodsField isolates from Papua, Indonesia, underwent ex vivo drug susceptibility testing against chloroquine, amodiaquine, piperaquine, mefloquine, and artesunate. A single nucleic acid stain (i.e., hydroethidine (HE) for P. falciparum and SYBR Green I (SG) for P. vivax) was used to quantify infected red blood cells by FC-based signal detection. Data derived by FC were compared to standard quantification by light microscopy (LM). A subset of isolates was used to compare single and double staining techniques.ResultsIn total, 57 P. falciparum and 23 P. vivax field isolates were collected for ex vivo drug susceptibility testing. Reliable paired data between LM and FC was obtained for 88 % (295/334) of these assays. The median difference of derived IC50 values varied from −5.4 to 6.1 nM, associated with 0.83–1.23 fold change in IC50 values between LM and FC. In 15 assays (5.1 %), the derived difference of IC50 estimates was beyond the 95 % limits of agreement; in eleven assays (3.7 %), this was attributable to low parasite growth (final schizont count < 40 %), and in four assays (1.4 %) due to low initial parasitaemia at the start of assay (<2000 µl−1). In a subset of seven samples, LM, single and double staining FC techniques generated similar IC50 values.ConclusionsA single staining FC-based assay using a portable cytometer provides a simple, fast and versatile platform for field surveillance of ex vivo drug susceptibility in clinical P. falciparum and P. vivax isolates.
- Published
- 2015
4. Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax
- Author
-
Wirjanata, Grennady, Sebayang, Boni F., Chalfein, Ferryanto, Prayoga, Pak, Handayuni, Irene, Trianty, Leily, Kenangalem, Enny, Noviyanti, Rintis, Campo, Brice, Poespoprodjo, Jeanne R., Mohrle, Jorg J., Price, Ric N., Marfurt, Jutta, Wirjanata, Grennady, Sebayang, Boni F., Chalfein, Ferryanto, Prayoga, Pak, Handayuni, Irene, Trianty, Leily, Kenangalem, Enny, Noviyanti, Rintis, Campo, Brice, Poespoprodjo, Jeanne R., Mohrle, Jorg J., Price, Ric N., and Marfurt, Jutta
- Abstract
The 4-aminoquinoline naphthoquine (NQ) and the thiazine dye methylene blue (MB) have potent in vitro efficacies against Plasmodium falciparum, but susceptibility data for P. vivax are limited. The species- and stage-specific ex vivo activities of NQ and MB were assessed using a modified schizont maturation assay on clinical field isolates from Papua, Indonesia, where multidrug-resistant P. falciparum and P. vivax are prevalent. Both compounds were highly active against P. falciparum (median [range] 50% inhibitory concentration [IC50]: NQ, 8.0 nM [2.6 to 71.8 nM]; and MB, 1.6 nM [0.2 to 7.0 nM]) and P. vivax (NQ, 7.8 nM [1.5 to 34.2 nM]; and MB, 1.2 nM [0.4 to 4.3 nM]). Stage-specific drug susceptibility assays revealed significantly greater IC50s in parasites exposed at the trophozoite stage than at the ring stage for NQ in P. falciparum (26.5 versus 5.1 nM, P = 0.021) and P. vivax (341.6 versus 6.5 nM, P = 0.021) and for MB in P. vivax (10.1 versus 1.6 nM, P = 0.010). The excellent ex vivo activities of NQ and MB against both P. falciparum and P. vivax highlight their potential utility for the treatment of multidrug-resistant malaria in areas where both species are endemic.
- Published
- 2015
5. Contrasting Ex Vivo Efficacies of 'Reversed Chloroquine' Compounds in Chloroquine-Resistant Plasmodium falciparum and P. vivax Isolates
- Author
-
Wirjanata, Grennady, Sebayang, Boni F., Chalfein, Ferryanto, Prayoga, Pak, Handayuni, Irene, Noviyanti, Rintis, Kenangalem, Enny, Poespoprodjo, Jeanne R., Burgess, Steven J., Peyton, David H., Price, Ric N., Marfurt, Jutta, Wirjanata, Grennady, Sebayang, Boni F., Chalfein, Ferryanto, Prayoga, Pak, Handayuni, Irene, Noviyanti, Rintis, Kenangalem, Enny, Poespoprodjo, Jeanne R., Burgess, Steven J., Peyton, David H., Price, Ric N., and Marfurt, Jutta
- Abstract
Chloroquine (CQ) has been the mainstay of malaria treatment for more than 60 years. However, the emergence and spread of CQ resistance now restrict its use to only a few areas where malaria is endemic. The aim of the present study was to investigate whether a novel combination of a CQ-like moiety and an imipramine-like pharmacophore can reverse CQ resistance ex vivo. Between March to October 2011 and January to September 2013, two “reversed chloroquine” (RCQ) compounds (PL69 and PL106) were tested against multidrug-resistant field isolates of Plasmodium falciparum (n = 41) and Plasmodium vivax (n = 45) in Papua, Indonesia, using a modified ex vivo schizont maturation assay. The RCQ compounds showed high efficacy against both CQ-resistant P. falciparum and P. vivax field isolates. For P. falciparum, the median 50% inhibitory concentrations (IC50s) were 23.2 nM for PL69 and 26.6 nM for PL106, compared to 79.4 nM for unmodified CQ (P < 0.001 and P = 0.036, respectively). The corresponding values for P. vivax were 19.0, 60.0, and 60.9 nM (P < 0.001 and P = 0.018, respectively). There was a significant correlation between IC50s of CQ and PL69 (Spearman's rank correlation coefficient [rs] = 0.727, P < 0.001) and PL106 (rs = 0.830, P < 0.001) in P. vivax but not in P. falciparum. Both RCQs were equally active against the ring and trophozoite stages of P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and 172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM). RCQ compounds have enhanced ex vivo activity against CQ-resistant clinical isolates of P. falciparum and P. vivax, suggesting the potential use of reversal agents in antimalarial drug development. Interspecies differences in RCQ compound activity may indicate differences in CQ pharmacokinetics between the two Plasmodium species.
- Published
- 2015
6. Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry
- Author
-
Wirjanata, Grennady, primary, Handayuni, Irene, additional, Prayoga, Pak, additional, Apriyanti, Dwi, additional, Chalfein, Ferryanto, additional, Sebayang, Boni F., additional, Kho, Steven, additional, Noviyanti, Rintis, additional, Kenangalem, Enny, additional, Campo, Brice, additional, Poespoprodjo, Jeanne Rini, additional, Price, Ric N., additional, and Marfurt, Jutta, additional
- Published
- 2015
- Full Text
- View/download PDF
7. Comparative Ex Vivo Activity of Novel Endoperoxides in Multidrug-Resistant Plasmodium falciparum and P. vivax
- Author
-
Marfurt, Jutta, Chalfein, Ferryanto, Prayoga, Pak, Wabiser, Frans, Wirjanata, Grennady, Sebayang, Boni, Piera, Kim A., Wittlin, Sergio, Haynes, Richard K., Möhrle, Jörg J., Anstey, Nicholas M., Kenangalem, Enny, Price, Ric N., Marfurt, Jutta, Chalfein, Ferryanto, Prayoga, Pak, Wabiser, Frans, Wirjanata, Grennady, Sebayang, Boni, Piera, Kim A., Wittlin, Sergio, Haynes, Richard K., Möhrle, Jörg J., Anstey, Nicholas M., Kenangalem, Enny, and Price, Ric N.
- Abstract
The declining efficacy of artemisinin derivatives against Plasmodium falciparum highlights the urgent need to identify alternative highly potent compounds for the treatment of malaria. In Papua Indonesia, where multidrug resistance has been documented against both P. falciparum and P. vivax malaria, comparative ex vivo antimalarial activity against Plasmodium isolates was assessed for the artemisinin derivatives artesunate (AS) and dihydroartemisinin (DHA), the synthetic peroxides OZ277 and OZ439, the semisynthetic 10-alkylaminoartemisinin derivatives artemisone and artemiside, and the conventional antimalarial drugs chloroquine (CQ), amodiaquine (AQ), and piperaquine (PIP). Ex vivo drug susceptibility was assessed in 46 field isolates (25 P. falciparum and 21 P. vivax). The novel endoperoxide compounds exhibited potent ex vivo activity against both species, but significant differences in intrinsic activity were observed. Compared to AS and its active metabolite DHA, all the novel compounds showed lower or equal 50% inhibitory concentrations (IC50s) in both species (median IC50s between 1.9 and 3.6 nM in P. falciparum and 0.7 and 4.6 nM in P. vivax). The antiplasmodial activity of novel endoperoxides showed different cross-susceptibility patterns in the two Plasmodium species: whereas their ex vivo activity correlated positively with CQ, PIP, AS, and DHA in P. falciparum, the same was not apparent in P. vivax. The current study demonstrates for the first time potent activity of novel endoperoxides against drug-resistant P. vivax. The high activity against drug-resistant strains of both Plasmodium species confirms these compounds to be promising candidates for future artemisinin-based combination therapy (ACT) regimens in regions of coendemicity.
- Published
- 2012
8. Ex Vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax
- Author
-
Marfurt, Jutta, Chalfein, Ferryanto, Prayoga, Pak, Wabiser, Frans, Kenangalem, Enny, Piera, Kim A., MacHunter, Barbara, Tjitra, Emiliana, Anstey, Nicholas M., Price, Ric N., Marfurt, Jutta, Chalfein, Ferryanto, Prayoga, Pak, Wabiser, Frans, Kenangalem, Enny, Piera, Kim A., MacHunter, Barbara, Tjitra, Emiliana, Anstey, Nicholas M., and Price, Ric N.
- Abstract
Ferroquine (FQ; SSR97193), a ferrocene-containing 4-aminoquinoline derivate, has potent in vitro efficacy against chloroquine (CQ)-resistant Plasmodium falciparum and CQ-sensitive P. vivax. In the current study, ex vivo FQ activity was tested in multidrug-resistant P. falciparum and P. vivax field isolates using a schizont maturation assay. Although FQ showed excellent activity against CQ-sensitive and -resistant P. falciparum and P. vivax (median 50% inhibitory concentrations [IC50s], 9.6 nM and 18.8 nM, respectively), there was significant cross-susceptibility with the quinoline-based drugs chloroquine, amodiaquine, and piperaquine (for P. falciparum, r = 0.546 to 0.700, P < 0.001; for P. vivax, r = 0.677 to 0.821, P < 0.001). The observed ex vivo cross-susceptibility is likely to reflect similar mechanisms of drug uptake/efflux and modes of drug action of this drug class. However, the potent activity of FQ against resistant isolates of both P. falciparum and P. vivax highlights a promising role for FQ as a lead antimalarial against CQ-resistant Plasmodium and a useful partner drug for artemisinin-based combination therapy.
- Published
- 2011
9. In Vivo and In Vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia
- Author
-
Seswantoro H., Russell, Barry, Ratcliff, A., Prasetyorini, B., Chalfein, Ferryanto, Marfurt, Jutta, Kenangalem, Enny, Wuwung, M., Piera, Kim A., Ebsworth, E. P., Anstey, Nicholas M., Tjitra, Emiliana, Price, Ric N., Seswantoro H., Russell, Barry, Ratcliff, A., Prasetyorini, B., Chalfein, Ferryanto, Marfurt, Jutta, Kenangalem, Enny, Wuwung, M., Piera, Kim A., Ebsworth, E. P., Anstey, Nicholas M., Tjitra, Emiliana, and Price, Ric N.
- Abstract
Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that chloroquine resistance may be emerging in P. malariae and P. ovale. In order to assess this, in vivo and in vitro efficacy studies were conducted in patients with monoinfection in Papua, Indonesia. Consecutive patients with uncomplicated malaria due to P. ovale or P. malariae were enrolled in a prospective clinical trial, provided with supervised chloroquine treatment, and followed for 28 days. Blood from patients with P. malariae or P. ovale parasitemia greater than 1,000 per microliter underwent in vitro antimalarial drug susceptibility testing using a modified schizont maturation assay. Of the 57 evaluable patients in the clinical study (P. malariae, n = 46; P. ovale, n = 11), none had recurrence with the same species during follow-up. The mean parasite reduction ratio at 48 h was 86 (95% confidence interval [CI], 57 to 114) for P. malariae and 150 (95% CI, 54 to 245) for P. ovale (P = 0.18). One patient infected with P. malariae, with 93% of parasites at the trophozoite stage, was still parasitemic on day 4. In vitro drug susceptibility assays were carried out successfully for 40 isolates (34 infected with P. malariae and 6 with P. ovale). The P. malariae infections at trophozoite stages had significantly higher chloroquine 50% effective concentrations (EC50s) (median, 127.9 nM [range, 7.9 to 2,980]) than those initially exposed at the ring stage (median, 14.0 nM [range, 3.5 to 27.0]; P = 0.01). The EC50 for chloroquine in P. ovale was also higher in an isolate initially at the trophozoite stage (23.2 nM) than in the three isolates predominantly at ring stage (7.8 nM). Chloroquine retains adequate efficacy against P. ovale and P. malariae, but its marked stage specificity of action may account for reports of delayed parasite clearance times.
- Published
- 2011
10. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax
- Author
-
Marfurt, Jutta, Chalfein, Ferryanto, Prayoga, Pak, Wabiser, Frans, Kenangalem, Enny, Piera, Kim A., Fairlie, David, Tjitra, Emiliana, Anstey, Nicholas M., Andrews, Kathy, Price, Ric N., Marfurt, Jutta, Chalfein, Ferryanto, Prayoga, Pak, Wabiser, Frans, Kenangalem, Enny, Piera, Kim A., Fairlie, David, Tjitra, Emiliana, Anstey, Nicholas M., Andrews, Kathy, and Price, Ric N.
- Abstract
Histone acetylation plays an important role in regulating gene transcription and silencing in Plasmodium falciparum. Histone deacetylase (HDAC) inhibitors, particularly those of the hydroxamate class, have been shown to have potent in vitro activity against drug-resistant and -sensitive laboratory strains of P. falciparum, raising their potential as a new class of antimalarial compounds. In the current study, stage-specific ex vivo susceptibility profiles of representative hydroxamate-based HDAC inhibitors suberoylanilide hydroxamic acid (SAHA), 2-ASA-9, and 2-ASA-14 (2-ASA-9 and 2-ASA-14 are 2-aminosuberic acid-based HDAC inhibitors) were assessed in multidrug-resistant clinical isolates of P. falciparum (n 24) and P. vivax (n 25) from Papua, Indonesia, using a modified schizont maturation assay. Submicromolar concentrations of SAHA, 2-ASA-9, and 2-ASA-14 inhibited the growth of both P. falciparum (median 50% inhibitory concentrations [IC50s] of 310, 533, and 266 nM) and P. vivax (median IC50s of 170, 503, and 278 nM). Inverse correlation patterns between HDAC inhibitors and chloroquine for P. falciparum and mefloquine for P. vivax indicate species-specific susceptibility profiles for HDAC inhibitors. These HDAC inhibitors were also found to be potent ex vivo against P. vivax schizont maturation, comparable to that in P. falciparum, suggesting that HDAC inhibitors may be promising candidates for antimalarial therapy in geographical locations where both species are endemic. Further studies optimizing the selectivity and in vivo efficacy of HDAC inhibitors in Plasmodium spp. and defining drug interaction with common antimalarial compounds are warranted to investigate the role of HDAC inhibitors in antimalarial therapy.
- Published
- 2010
11. In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax
- Author
-
Price, Ric N., Marfurt, Jutta, Chalfein, Ferryanto, Kenangalem, Enny, Piera, Kim A., Tjitra, Emiliana, Anstey, Nicholas M., Russell, Bruce, Price, Ric N., Marfurt, Jutta, Chalfein, Ferryanto, Kenangalem, Enny, Piera, Kim A., Tjitra, Emiliana, Anstey, Nicholas M., and Russell, Bruce
- Abstract
Pyronaridine, a Mannich base antimalarial, has demonstrated high in vivo and in vitro efficacy against chloroquine-resistant Plasmodium falciparum. Although this drug has the potential to become a prominent artemisinin combination therapy, little is known about its efficacy against drug-resistant Plasmodium vivax. The in vitro antimalarial susceptibility of pyronaridine was assessed in multidrug-resistant P. vivax (n = 99) and P. falciparum (n = 90) isolates from Papua, Indonesia, using a schizont maturation assay. The median 50% inhibitory concentration (IC50) of pyronaridine was 1.92 nM (range, 0.24 to 13.8 nM) against P. falciparum and 2.58 nM (range, 0.13 to 43.6 nM) against P. vivax, with in vitro susceptibility correlating significantly with chloroquine, amodiaquine, and piperaquine (rs [Spearman's rank correlation coefficient] = 0.45 to 0.62; P < 0.001). P. falciparum parasites initially at trophozoite stage had higher IC50s of pyronaridine than those exposed at the ring stage (8.9 nM [range, 0.6 to 8.9 nM] versus 1.6 nM [range, 0.6 to 8.9 nM], respectively; P = 0.015), although this did not reach significance for P. vivax (4.7 nM [range, 1.4 to 18.7 nM] versus 2.5 nM [range, 1.4 to 15.6 nM], respectively; P = 0.085). The excellent in vitro efficacy of pyronaridine against both chloroquine-resistant P. vivax and P. falciparum highlights the suitability of the drug as a novel partner for artemisinin-based combination therapy in regions where the two species are coendemic.
- Published
- 2010
12. In Vivo and In Vitro Efficacy of Amodiaquine Monotherapy for Treatment of Infection by Chloroquine-Resistant Plasmodium vivax
- Author
-
Hasugian, A. R., Tjitra, Emiliana, Ratcliff, A., Siswantoro, H., Kenangalem, Enny, Wuwung, R. M., Purba, H. L. E., Piera, K., Chalfein, Ferryanto, Marfurt, Jutta, Penttinen, P. M. P., Russell, Bruce, Anstey, Nicholas M., Price, Ric N., Hasugian, A. R., Tjitra, Emiliana, Ratcliff, A., Siswantoro, H., Kenangalem, Enny, Wuwung, R. M., Purba, H. L. E., Piera, K., Chalfein, Ferryanto, Marfurt, Jutta, Penttinen, P. M. P., Russell, Bruce, Anstey, Nicholas M., and Price, Ric N.
- Abstract
Amodiaquine retains efficacy against infection by chloroquine-resistant Plasmodium falciparum; however, little information is available on its efficacy against infection by chloroquine-resistant Plasmodium vivax. Patients presenting to a rural clinic with a pure P. vivax infection that recurred after recent antimalarial treatment were retreated, this time with amodiaquine monotherapy, and the risk of further recurrence within 4 weeks was assessed. Of the 87 patients with pure P. vivax infection, 15 patients did not complete a full course of treatment, 4 of whom were intolerant to treatment. In the 72 patients completing treatment, 91% (63 of 69) had cleared their parasitemia within 48 h with no early treatment failure. Follow-up to day 28 or recurrent parasitemia was achieved for 56 patients (78%). The cumulative incidence of treatment failure by day 28 was 22.8% (95% confidence interval, 7.3 to 38%). The in vitro sensitivity profile was determined for a separate set of isolates from outpatients with pure P. vivax infection. The median 50% inhibitory concentration of amodiaquine was 11.3 nM (range, 0.37 to 95.8) and was correlated significantly with that of chloroquine (Spearman rank correlation coefficient, 0.602; P < 0.001) Although amodiaquine results in a rapid clinical response, the risk of recurrence by day 28 is unacceptably high, reducing its suitability as an alternative treatment of infection by chloroquine-resistant P. vivax in this region.
- Published
- 2009
13. Determinants of In Vitro Drug Susceptibility Testing of Plasmodium vivax
- Author
-
Russell, Bruce, Chalfein, Ferryanto, Prasetyorini, B., Kenangalem, Enny, Piera, Kim A., Suwanarusk, Rossarin, Brockman, Alan, Prayoga, Pak, Sugiarto, P., Cheng, Qi, Tjitra, Emiliana, Anstey, Nicholas M., Price, Erin P., Russell, Bruce, Chalfein, Ferryanto, Prasetyorini, B., Kenangalem, Enny, Piera, Kim A., Suwanarusk, Rossarin, Brockman, Alan, Prayoga, Pak, Sugiarto, P., Cheng, Qi, Tjitra, Emiliana, Anstey, Nicholas M., and Price, Erin P.
- Abstract
In Papua, Indonesia, the antimalarial susceptibility of Plasmodium vivax (n = 216) and P. falciparum (n = 277) was assessed using a modified schizont maturation assay for chloroquine, amodiaquine, artesunate, lumefantrine, mefloquine, and piperaquine. The most effective antimalarial against P. vivax and P. falciparum was artesunate, with geometric mean 50% inhibitory concentrations (IC50s) (95% confidence intervals [CI]) of 1.31 nM (1.07 to 1.59) and 0.64 nM (0.53 to 0.79), respectively. In contrast, the geometric mean chloroquine IC50 for P. vivax was 295 nM (227 to 384) compared to only 47.4 nM (42.2 to 53.3) for P. falciparum. Two factors were found to significantly influence the in vitro drug response of P. vivax: the initial stage of the parasite and the duration of the assay. Isolates of P. vivax initially at the trophozoite stage had significantly higher chloroquine IC50s (478 nM [95% CI, 316 to 722]) than those initially at the ring stage (84.7 nM [95% CI, 45.7 to 157]; P < 0.001). Synchronous isolates of P. vivax and P. falciparum which reached the target of 40% schizonts in the control wells within 30 h had significantly higher geometric mean chloroquine IC50s (435 nM [95% CI, 169 to 1,118] and 55.9 nM [95% CI, 48 to 64.9], respectively) than isolates that took more than 30 h (39.9 nM [14.6 to 110.4] and 36.9 nM [31.2 to 43.7]; P < 0.005). The results demonstrate the marked stage-specific activity of chloroquine with P. vivax and suggest that susceptibility to chloroquine may be associated with variable growth rates. These findings have important implications for the phenotypic and downstream genetic characterization of P. vivax.
- Published
- 2008
14. Amplification of pvmdr1 Associated with Multidrug-Resistant Plasmodium vivax
- Author
-
Suwanarusk, Rossarin, Chavchich, M., Russell, B., Jaidee, A., Chalfein, Ferryanto, Barends, M., Prasetyorini, B., Kenangalem, Enny, Piera, Kim A., Lek-uthai, U., Anstey, Nicholas M., Tjitra, Emiliana, Nosten, F.., Cheng, Qi, Price, Ric N., Suwanarusk, Rossarin, Chavchich, M., Russell, B., Jaidee, A., Chalfein, Ferryanto, Barends, M., Prasetyorini, B., Kenangalem, Enny, Piera, Kim A., Lek-uthai, U., Anstey, Nicholas M., Tjitra, Emiliana, Nosten, F.., Cheng, Qi, and Price, Ric N.
- Published
- 2008
15. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms
- Author
-
Suwanarusk, Rossarin, Russell, Bruce, Chavchich, Marina, Chalfein, Ferryanto, Kenangalem, Enny, Kosaisavee, Varakom, Prasetyorini, Budi, Piera, Kim A., Barends, Marion, Brockman, Alan, Lek-Uthai, Usa, Anstey, Nicholas M., Tjitra, Emiliana, Nosten, Francois, Cheng, Qin, Price, Ric N., Suwanarusk, Rossarin, Russell, Bruce, Chavchich, Marina, Chalfein, Ferryanto, Kenangalem, Enny, Kosaisavee, Varakom, Prasetyorini, Budi, Piera, Kim A., Barends, Marion, Brockman, Alan, Lek-Uthai, Usa, Anstey, Nicholas M., Tjitra, Emiliana, Nosten, Francois, Cheng, Qin, and Price, Ric N.
- Abstract
BackgroundTreatment failure of chloroquine for P. vivax infections has reached high levels in the eastern provinces of Indonesia, however, in vitro characterization of chloroquine resistance and its associated molecular profile have yet to be determined.MethodsUsing a modified schizont maturation assay we investigated the in vitro chloroquine susceptibility profile and molecular polymorphisms of P. vivax isolates collected from Papua, Indonesia, where high levels of clinical chloroquine treatment failure have been reported, and from Thailand, where chloroquine treatment is generally effective.ResultsThe geometric mean chloroquine IC50 for P. vivax isolates from Papua (n = 145) was 312 nM [95%CI: 237–411 nM] compared to 46.8 nM [95%CI: 34.7–63.1 nM] from Thailand (n = 81); p<0.001. Correlating with the known clinical efficacy of the area, a cut off for chloroquine resistance was defined as 220nM, a level exceeded in 13.6% (11/81) of Thai isolates and 65% (94/145) of Papuan isolates; p<0.001. Several sequence polymorphisms in pvcrt-o and pvmdr1, and difference in pvmdr1 copy number were identified. A Y976F mutation in pvmdr1 was present in 96% (123/128) of Papuan isolates and 25% (17/69) of Thai isolates; p<0.001. Overall, the geometric mean chloroquine IC50 in isolates with the Y976F mutation was 283 nM [95%CI: 211–379], compared to 44.5 nM [95%CI: 31.3–63.4] in isolates with the wild type; p< 0.001. Pvmdr1 amplification occurred in 23% (15/66) of Thai isolates compared to none (0/104) of Indonesian isolates (p<0.001), but was not associated with increased chloroquine resistance after controlling for geographical location.ConclusionsIn vitro susceptibility testing of P. vivax discriminates between populations with differing levels of clinical efficacy of chloroquine. The pvmdr1 polymorphism at Y976F may provide a useful tool to highlight areas of emerging chloroquine resistance, although further studies defining its clinical cor
- Published
- 2007
16. Comparative Ex Vivo Activity of Novel Endoperoxides in Multidrug-Resistant Plasmodium falciparum and P. vivax
- Author
-
Marfurt, Jutta, primary, Chalfein, Ferryanto, additional, Prayoga, Pak, additional, Wabiser, Frans, additional, Wirjanata, Grennady, additional, Sebayang, Boni, additional, Piera, Kim A., additional, Wittlin, Sergio, additional, Haynes, Richard K., additional, Möhrle, Jörg J., additional, Anstey, Nicholas M., additional, Kenangalem, Enny, additional, and Price, Ric N., additional
- Published
- 2012
- Full Text
- View/download PDF
17. Ex Vivo Drug Susceptibility of Ferroquine against Chloroquine-Resistant Isolates of Plasmodium falciparum and P. vivax
- Author
-
Marfurt, Jutta, primary, Chalfein, Ferryanto, additional, Prayoga, Pak, additional, Wabiser, Frans, additional, Kenangalem, Enny, additional, Piera, Kim A., additional, MacHunter, Barbara, additional, Tjitra, Emiliana, additional, Anstey, Nicholas M., additional, and Price, Ric N., additional
- Published
- 2011
- Full Text
- View/download PDF
18. Ex Vivo Activity of Histone Deacetylase Inhibitors against Multidrug-Resistant Clinical Isolates of Plasmodium falciparum and P. vivax
- Author
-
Marfurt, Jutta, primary, Chalfein, Ferryanto, additional, Prayoga, Pak, additional, Wabiser, Frans, additional, Kenangalem, Enny, additional, Piera, Kim A., additional, Fairlie, David P., additional, Tjitra, Emiliana, additional, Anstey, Nicholas M., additional, Andrews, Kathy T., additional, and Price, Ric N., additional
- Published
- 2011
- Full Text
- View/download PDF
19. Chloroquine Resistant Plasmodium vivax: In Vitro Characterisation and Association with Molecular Polymorphisms
- Author
-
Suwanarusk, Rossarin, primary, Russell, Bruce, additional, Chavchich, Marina, additional, Chalfein, Ferryanto, additional, Kenangalem, Enny, additional, Kosaisavee, Varakorn, additional, Prasetyorini, Budi, additional, Piera, Kim A., additional, Barends, Marion, additional, Brockman, Alan, additional, Lek-Uthai, Usa, additional, Anstey, Nicholas M., additional, Tjitra, Emiliana, additional, Nosten, François, additional, Cheng, Qin, additional, and Price, Ric N., additional
- Published
- 2007
- Full Text
- View/download PDF
20. Potent Ex VivoActivity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparumand Plasmodium vivax
- Author
-
Wirjanata, Grennady, Sebayang, Boni F., Chalfein, Ferryanto, Prayoga, Handayuni, Irene, Trianty, Leily, Kenangalem, Enny, Noviyanti, Rintis, Campo, Brice, Poespoprodjo, Jeanne Rini, Möhrle, Jörg J., Price, Ric N., and Marfurt, Jutta
- Abstract
ABSTRACTThe 4-aminoquinoline naphthoquine (NQ) and the thiazine dye methylene blue (MB) have potent in vitroefficacies against Plasmodium falciparum, but susceptibility data for P. vivaxare limited. The species- and stage-specific ex vivoactivities of NQ and MB were assessed using a modified schizont maturation assay on clinical field isolates from Papua, Indonesia, where multidrug-resistant P. falciparumand P. vivaxare prevalent. Both compounds were highly active against P. falciparum(median [range] 50% inhibitory concentration [IC50]: NQ, 8.0 nM [2.6 to 71.8 nM]; and MB, 1.6 nM [0.2 to 7.0 nM]) and P. vivax(NQ, 7.8 nM [1.5 to 34.2 nM]; and MB, 1.2 nM [0.4 to 4.3 nM]). Stage-specific drug susceptibility assays revealed significantly greater IC50s in parasites exposed at the trophozoite stage than at the ring stage for NQ in P. falciparum(26.5 versus 5.1 nM, P= 0.021) and P. vivax(341.6 versus 6.5 nM, P= 0.021) and for MB in P. vivax(10.1 versus 1.6 nM, P= 0.010). The excellent ex vivoactivities of NQ and MB against both P. falciparumand P. vivaxhighlight their potential utility for the treatment of multidrug-resistant malaria in areas where both species are endemic.
- Published
- 2015
- Full Text
- View/download PDF
21. Contrasting Ex VivoEfficacies of “Reversed Chloroquine” Compounds in Chloroquine-Resistant Plasmodium falciparumand P. vivaxIsolates
- Author
-
Wirjanata, Grennady, Sebayang, Boni F., Chalfein, Ferryanto, Prayoga, Handayuni, Irene, Noviyanti, Rintis, Kenangalem, Enny, Poespoprodjo, Jeanne Rini, Burgess, Steven J., Peyton, David H., Price, Ric N., and Marfurt, Jutta
- Abstract
ABSTRACTChloroquine (CQ) has been the mainstay of malaria treatment for more than 60 years. However, the emergence and spread of CQ resistance now restrict its use to only a few areas where malaria is endemic. The aim of the present study was to investigate whether a novel combination of a CQ-like moiety and an imipramine-like pharmacophore can reverse CQ resistance ex vivo. Between March to October 2011 and January to September 2013, two “reversed chloroquine” (RCQ) compounds (PL69 and PL106) were tested against multidrug-resistant field isolates of Plasmodium falciparum(n= 41) and Plasmodium vivax(n= 45) in Papua, Indonesia, using a modified ex vivoschizont maturation assay. The RCQ compounds showed high efficacy against both CQ-resistant P. falciparumand P. vivaxfield isolates. For P. falciparum, the median 50% inhibitory concentrations (IC50s) were 23.2 nM for PL69 and 26.6 nM for PL106, compared to 79.4 nM for unmodified CQ (P< 0.001 and P= 0.036, respectively). The corresponding values for P. vivaxwere 19.0, 60.0, and 60.9 nM (P< 0.001 and P= 0.018, respectively). There was a significant correlation between IC50s of CQ and PL69 (Spearman's rank correlation coefficient [rs] = 0.727, P< 0.001) and PL106 (rs= 0.830, P< 0.001) in P. vivaxbut not in P. falciparum. Both RCQs were equally active against the ring and trophozoite stages of P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and 172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM). RCQ compounds have enhanced ex vivoactivity against CQ-resistant clinical isolates of P. falciparumand P. vivax, suggesting the potential use of reversal agents in antimalarial drug development. Interspecies differences in RCQ compound activity may indicate differences in CQ pharmacokinetics between the two Plasmodiumspecies.
- Published
- 2015
- Full Text
- View/download PDF
22. Comparative Ex VivoActivity of Novel Endoperoxides in Multidrug-Resistant Plasmodium falciparumand P. vivax
- Author
-
Marfurt, Jutta, Chalfein, Ferryanto, Prayoga, Pak, Wabiser, Frans, Wirjanata, Grennady, Sebayang, Boni, Piera, Kim A., Wittlin, Sergio, Haynes, Richard K., Möhrle, Jörg J., Anstey, Nicholas M., Kenangalem, Enny, and Price, Ric N.
- Abstract
ABSTRACTThe declining efficacy of artemisinin derivatives against Plasmodium falciparumhighlights the urgent need to identify alternative highly potent compounds for the treatment of malaria. In Papua Indonesia, where multidrug resistance has been documented against both P. falciparumand P. vivaxmalaria, comparative ex vivoantimalarial activity against Plasmodiumisolates was assessed for the artemisinin derivatives artesunate (AS) and dihydroartemisinin (DHA), the synthetic peroxides OZ277 and OZ439, the semisynthetic 10-alkylaminoartemisinin derivatives artemisone and artemiside, and the conventional antimalarial drugs chloroquine (CQ), amodiaquine (AQ), and piperaquine (PIP). Ex vivodrug susceptibility was assessed in 46 field isolates (25 P. falciparumand 21 P. vivax). The novel endoperoxide compounds exhibited potent ex vivoactivity against both species, but significant differences in intrinsic activity were observed. Compared to AS and its active metabolite DHA, all the novel compounds showed lower or equal 50% inhibitory concentrations (IC50s) in both species (median IC50s between 1.9 and 3.6 nM in P. falciparumand 0.7 and 4.6 nM in P. vivax). The antiplasmodial activity of novel endoperoxides showed different cross-susceptibility patterns in the two Plasmodiumspecies: whereas their ex vivoactivity correlated positively with CQ, PIP, AS, and DHA in P. falciparum, the same was not apparent in P. vivax. The current study demonstrates for the first time potent activity of novel endoperoxides against drug-resistant P. vivax. The high activity against drug-resistant strains of both Plasmodiumspecies confirms these compounds to be promising candidates for future artemisinin-based combination therapy (ACT) regimens in regions of coendemicity.
- Published
- 2012
- Full Text
- View/download PDF
23. Ex VivoDrug Susceptibility of Ferroquine against Chloroquine-Resistant Isolates of Plasmodium falciparumand P. vivax
- Author
-
Marfurt, Jutta, Chalfein, Ferryanto, Prayoga, Pak, Wabiser, Frans, Kenangalem, Enny, Piera, Kim A., MacHunter, Barbara, Tjitra, Emiliana, Anstey, Nicholas M., and Price, Ric N.
- Abstract
ABSTRACTFerroquine (FQ; SSR97193), a ferrocene-containing 4-aminoquinoline derivate, has potent in vitroefficacy against chloroquine (CQ)-resistant Plasmodium falciparumand CQ-sensitive P. vivax. In the current study, ex vivoFQ activity was tested in multidrug-resistant P. falciparumand P. vivaxfield isolates using a schizont maturation assay. Although FQ showed excellent activity against CQ-sensitive and -resistant P. falciparumand P. vivax(median 50% inhibitory concentrations [IC50s], 9.6 nM and 18.8 nM, respectively), there was significant cross-susceptibility with the quinoline-based drugs chloroquine, amodiaquine, and piperaquine (for P. falciparum, r= 0.546 to 0.700, P< 0.001; for P. vivax, r= 0.677 to 0.821, P< 0.001). The observed ex vivocross-susceptibility is likely to reflect similar mechanisms of drug uptake/efflux and modes of drug action of this drug class. However, the potent activity of FQ against resistant isolates of both P. falciparumand P. vivaxhighlights a promising role for FQ as a lead antimalarial against CQ-resistant Plasmodiumand a useful partner drug for artemisinin-based combination therapy.
- Published
- 2011
- Full Text
- View/download PDF
24. Ex VivoActivity of Histone Deacetylase Inhibitors against Multidrug-Resistant Clinical Isolates of Plasmodium falciparumand P. vivax
- Author
-
Marfurt, Jutta, Chalfein, Ferryanto, Prayoga, Pak, Wabiser, Frans, Kenangalem, Enny, Piera, Kim A., Fairlie, David P., Tjitra, Emiliana, Anstey, Nicholas M., Andrews, Kathy T., and Price, Ric N.
- Abstract
ABSTRACTHistone acetylation plays an important role in regulating gene transcription and silencing in Plasmodium falciparum. Histone deacetylase (HDAC) inhibitors, particularly those of the hydroxamate class, have been shown to have potent in vitroactivity against drug-resistant and -sensitive laboratory strains of P. falciparum, raising their potential as a new class of antimalarial compounds. In the current study, stage-specific ex vivosusceptibility profiles of representative hydroxamate-based HDAC inhibitors suberoylanilide hydroxamic acid (SAHA), 2-ASA-9, and 2-ASA-14 (2-ASA-9 and 2-ASA-14 are 2-aminosuberic acid-based HDAC inhibitors) were assessed in multidrug-resistant clinical isolates of P. falciparum(n= 24) and P. vivax(n= 25) from Papua, Indonesia, using a modified schizont maturation assay. Submicromolar concentrations of SAHA, 2-ASA-9, and 2-ASA-14 inhibited the growth of both P. falciparum(median 50% inhibitory concentrations [IC50s] of 310, 533, and 266 nM) and P. vivax(median IC50s of 170, 503, and 278 nM). Inverse correlation patterns between HDAC inhibitors and chloroquine for P. falciparumand mefloquine for P. vivaxindicate species-specific susceptibility profiles for HDAC inhibitors. These HDAC inhibitors were also found to be potent ex vivoagainst P. vivaxschizont maturation, comparable to that in P. falciparum, suggesting that HDAC inhibitors may be promising candidates for antimalarial therapy in geographical locations where both species are endemic. Further studies optimizing the selectivity and in vivoefficacy of HDAC inhibitors in Plasmodiumspp. and defining drug interaction with common antimalarial compounds are warranted to investigate the role of HDAC inhibitors in antimalarial therapy.
- Published
- 2010
- Full Text
- View/download PDF
25. Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax.
- Author
-
Wirjanata G, Sebayang BF, Chalfein F, Prayoga, Handayuni I, Trianty L, Kenangalem E, Noviyanti R, Campo B, Poespoprodjo JR, Möhrle JJ, Price RN, and Marfurt J
- Subjects
- Antimalarials pharmacology, Methylene Blue pharmacology, Plasmodium falciparum drug effects, Plasmodium vivax drug effects
- Abstract
The 4-aminoquinoline naphthoquine (NQ) and the thiazine dye methylene blue (MB) have potent in vitro efficacies against Plasmodium falciparum, but susceptibility data for P. vivax are limited. The species- and stage-specific ex vivo activities of NQ and MB were assessed using a modified schizont maturation assay on clinical field isolates from Papua, Indonesia, where multidrug-resistant P. falciparum and P. vivax are prevalent. Both compounds were highly active against P. falciparum (median [range] 50% inhibitory concentration [IC50]: NQ, 8.0 nM [2.6 to 71.8 nM]; and MB, 1.6 nM [0.2 to 7.0 nM]) and P. vivax (NQ, 7.8 nM [1.5 to 34.2 nM]; and MB, 1.2 nM [0.4 to 4.3 nM]). Stage-specific drug susceptibility assays revealed significantly greater IC50s in parasites exposed at the trophozoite stage than at the ring stage for NQ in P. falciparum (26.5 versus 5.1 nM, P = 0.021) and P. vivax (341.6 versus 6.5 nM, P = 0.021) and for MB in P. vivax (10.1 versus 1.6 nM, P = 0.010). The excellent ex vivo activities of NQ and MB against both P. falciparum and P. vivax highlight their potential utility for the treatment of multidrug-resistant malaria in areas where both species are endemic., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
26. Contrasting ex vivo efficacies of "reversed chloroquine" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates.
- Author
-
Wirjanata G, Sebayang BF, Chalfein F, Prayoga, Handayuni I, Noviyanti R, Kenangalem E, Poespoprodjo JR, Burgess SJ, Peyton DH, Price RN, and Marfurt J
- Subjects
- Antimalarials pharmacology, Chloroquine pharmacology, Humans, Inhibitory Concentration 50, Malaria drug therapy, Microbial Sensitivity Tests, Antimalarials therapeutic use, Chloroquine therapeutic use, Plasmodium falciparum drug effects, Plasmodium vivax drug effects
- Abstract
Chloroquine (CQ) has been the mainstay of malaria treatment for more than 60 years. However, the emergence and spread of CQ resistance now restrict its use to only a few areas where malaria is endemic. The aim of the present study was to investigate whether a novel combination of a CQ-like moiety and an imipramine-like pharmacophore can reverse CQ resistance ex vivo. Between March to October 2011 and January to September 2013, two "reversed chloroquine" (RCQ) compounds (PL69 and PL106) were tested against multidrug-resistant field isolates of Plasmodium falciparum (n = 41) and Plasmodium vivax (n = 45) in Papua, Indonesia, using a modified ex vivo schizont maturation assay. The RCQ compounds showed high efficacy against both CQ-resistant P. falciparum and P. vivax field isolates. For P. falciparum, the median 50% inhibitory concentrations (IC50s) were 23.2 nM for PL69 and 26.6 nM for PL106, compared to 79.4 nM for unmodified CQ (P < 0.001 and P = 0.036, respectively). The corresponding values for P. vivax were 19.0, 60.0, and 60.9 nM (P < 0.001 and P = 0.018, respectively). There was a significant correlation between IC50s of CQ and PL69 (Spearman's rank correlation coefficient [r s] = 0.727, P < 0.001) and PL106 (rs = 0.830, P < 0.001) in P. vivax but not in P. falciparum. Both RCQs were equally active against the ring and trophozoite stages of P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and 172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM). RCQ compounds have enhanced ex vivo activity against CQ-resistant clinical isolates of P. falciparum and P. vivax, suggesting the potential use of reversal agents in antimalarial drug development. Interspecies differences in RCQ compound activity may indicate differences in CQ pharmacokinetics between the two Plasmodium species., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.